The treatment of choice is ablative SBRT as long as liver constraints can be met. Kras/p53 wildtype CRC mets can be controled with 70%+ certainty at 5 years with 100Ghy BED, but Kras/p53 mut CRC mets are resistant (Hong, et al, JNCI,2017). For this reason, I use a BED of 150Gy but a dose that overco...